-
BioPharma Dive – AI / Data6 months ago
Rocket gene therapy cleared by FDA for rare immune disorder
Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of its value since...
-
BioPharma Dive – AI / Data6 months agoMerck’s deal for Terns sparks debate over a possible biotech bidding war
Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are convinced a better proposal is coming.
-
BioPharma Dive – AI / Data6 months agoFDA clears Denali drug in ‘clear step’ for rare disease biotechs
The approval of Denali’s Hunter syndrome treatment, Avlayah, comes after a series of drug rejections and delays that had led to criticism of the FDA’s stance...
-
BioPharma Dive – AI / Data6 months agoWave crashes on obesity drug update; Kodiak’s reboot pays dividends
Wave’s drug, which is meant to improve body composition, disappointed investors but was defended by analysts. Elsewhere, Kodiak’s revived vision loss treatment succeeded in a second...
-
BioPharma Dive – AI / Data6 months agoMaze tumbles despite positive data for kidney disease drug
Investors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease.
-
BioPharma Dive – AI / Data6 months agoBeam posts positive data on base editing treatment for AATD
Updated data showed the biotech’s approach to the rare lung and liver condition helped restore functional protective proteins in a small study.
-
BioPharma Dive – AI / Data6 months agoSarepta sees early success with RNAi drugs from Arrowhead
Long-awaited results from Phase 1/2 studies lifted Sarepta’s stock and, according to the company, suggest potential for two medicines to treat muscle-weakening conditions.
Psychedelic therapies ride wave of public favor into FDA hearing
After a brief storm of political headwinds, mRNA is back with strong momentum
STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
